OnKure Therapeutics, Inc. (OKUR)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch OKUR
See up to 3 months of OKUR. The 7-day demo opens the 1M and 3M ranges and puts OKUR on your watchlist.
Start 7-day demoLatest OKUR insider trades
About OnKure Therapeutics, Inc. (OKUR)
OnKure Therapeutics, Inc. is an SEC registrant, filing under CIK 0001637715, classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
OKUR Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 389 | $1K |
| Grant or award | 23 | 1,750,124 | |
| Derivative transaction | 12 | 1,016,024 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
OKUR insider transactions (Form 4)
5348 Form 4 filings on record, the earliest from Oct 8, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nicholas A. Saccomano - Officer | Open-market sale | Class A Common Stock | 87 | $2.97 footnote F2 | $259 | |
| ||||||
| Jason A. Leverone - Officer | Open-market sale | Class A Common Stock | 302 | $2.97 footnote F2 | $898 | |
| ||||||
| Edward T. Mathers - Director | Grant or award | Stock Option (right to buy) | 22,350 | $0.00 | - | |
| Liam Ratcliffe - Director | Grant or award | Stock Option (right to buy) | 22,350 | $0.00 | - | |
| Andrew John Phillips - Director | Grant or award | Stock Option (right to buy) | 22,350 | $0.00 | - | |
 Isaac Manke - Director | Grant or award | Stock Option (right to buy) | 300,000 | $0.00 | - | |
| Isaac Manke - Director | Derivative | Stock Option (right to buy) | 15,300 | - footnote F3,F4 | - | |
| Isaac Manke - Director | Grant or award | Stock Option (right to buy) | 15,300 | - footnote F3,F4 | - | |
| ||||||
| Valerie Malyvanh Jansen - Director | Grant or award | Stock Option (right to buy) | 22,350 | $0.00 | - | |
| Michael G. Grey - Director | Grant or award | Stock Option (right to buy) | 22,350 | $0.00 | - | |
| R. Michael Carruthers - Director | Grant or award | Stock Option (right to buy) | 22,350 | $0.00 | - | |
| Nicholas A. Saccomano - Officer | Grant or award | Employee Stock Option (right to buy) | 150,000 | $0.00 | - | |
| Nicholas A. Saccomano - Officer | Derivative | Employee Stock Option (right to buy) | 2,359 | - footnote F3,F4 | - | |
| Nicholas A. Saccomano - Officer | Grant or award | Employee Stock Option (right to buy) | 2,359 | - footnote F3,F4 | - | |
| Nicholas A. Saccomano - Officer | Derivative | Employee Stock Option (right to buy) | 1,485 | - footnote F3,F4 | - | |
| Nicholas A. Saccomano - Officer | Grant or award | Employee Stock Option (right to buy) | 1,485 | - footnote F3,F4 | - | |
| Nicholas A. Saccomano - Officer | Derivative | Employee Stock Option (right to buy) | 8,449 | - footnote F3,F4 | - | |
| Nicholas A. Saccomano - Officer | Grant or award | Employee Stock Option (right to buy) | 8,449 | - footnote F3,F4 | - | |
| Nicholas A. Saccomano - Officer | Derivative | Employee Stock Option (right to buy) | 16,898 | - footnote F3,F4 | - | |
| Nicholas A. Saccomano - Officer | Grant or award | Employee Stock Option (right to buy) | 16,898 | - footnote F3,F4 | - | |
| Nicholas A. Saccomano - Officer | Derivative | Employee Stock Option (right to buy) | 542,232 | - footnote F3,F4 | - | |
| Nicholas A. Saccomano - Officer | Grant or award | Employee Stock Option (right to buy) | 542,232 | - footnote F3,F4 | - | |
| ||||||
| Jason A. Leverone - Officer | Grant or award | Employee Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Jason A. Leverone - Officer | Derivative | Employee Stock Option (right to buy | 5,781 | - footnote F3,F4 | - | |
| Jason A. Leverone - Officer | Grant or award | Employee Stock Option (right to buy | 5,781 | - footnote F3,F4 | - | |
| Jason A. Leverone - Officer | Derivative | Employee Stock Option (right to buy) | 5,322 | - footnote F3,F4 | - | |
| Jason A. Leverone - Officer | Grant or award | Employee Stock Option (right to buy) | 5,322 | - footnote F3,F4 | - | |
| Jason A. Leverone - Officer | Derivative | Employee Stock Option (right to buy) | 130,611 | - footnote F3,F4 | - | |
| Jason A. Leverone - Officer | Grant or award | Employee Stock Option (right to buy) | 130,611 | - footnote F3,F4 | - | |
| ||||||
| Dylan Hartley - Officer | Grant or award | Employee Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Dylan Hartley - Officer | Derivative | Employee Stock Option (right to buy) | 137,603 | - footnote F3,F4 | - | |
| Dylan Hartley - Officer | Grant or award | Employee Stock Option (right to buy) | 137,603 | - footnote F3,F4 | - | |
| ||||||
| Samuel Agresta - Officer | Grant or award | Employee Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Samuel Agresta - Officer | Derivative | Employee Stock Option (right to buy) | 18,588 | - footnote F3,F4 | - | |
| Samuel Agresta - Officer | Grant or award | Employee Stock Option (right to buy) | 18,588 | - footnote F3,F4 | - | |
| Samuel Agresta - Officer | Derivative | Employee Stock Option (right to buy) | 131,396 | - footnote F3,F4 | - | |
| Samuel Agresta - Officer | Grant or award | Employee Stock Option (right to buy) | 131,396 | - footnote F3,F4 | - | |
| ||||||
| Nicholas A. Saccomano - Officer | Open-market sale | Class A Common Stock | 86 | $4.40 footnote F2 | $378 | |
| ||||||
| Jason A. Leverone - Officer | Open-market sale | Class A Common Stock | 303 | $4.40 footnote F2 | $1K | |
| ||||||
| Edward T. Mathers | Grant or award | Stock Option (right to buy) | 7,650 | $0.00 | - | |
| Liam Ratcliffe | Grant or award | Stock Option (right to buy) | 1,275 | $0.00 | - | |
| Andrew John Phillips | Grant or award | Stock Option (right to buy) | 7,650 | $0.00 | - | |
| Valerie Malyvanh Jansen | Grant or award | Stock Option (right to buy) | 7,650 | $0.00 | - | |
| Michael G. Grey | Grant or award | Stock Option (right to buy) | 7,650 | $0.00 | - | |
| R. Michael Carruthers | Grant or award | Stock Option (right to buy) | 7,650 | $0.00 | - | |
| Nicholas A. Saccomano - Officer | Grant or award | Employee Stock Option (right to buy) | 330,000 | $0.00 | - | |
| Jason A. Leverone - Officer | Grant or award | Employee Stock Option (right to buy) | 110,000 | $0.00 | - | |
| Dylan Hartley - Officer | Grant or award | Employee Stock Option (right to buy) | 110,000 | $0.00 | - | |
| Samuel Agresta - Officer | Grant or award | Employee Stock Option (right to buy) | 110,000 | $0.00 | - | |
| Liam Ratcliffe | Grant or award | Stock Option (right to buy) | 15,300 | $0.00 | - | |
| Nicholas A. Saccomano - Officer | Open-market sale | Class A Common Stock | 86 | $4.16 footnote F2 | $357 | |
| ||||||
| Jason A. Leverone - Officer | Open-market sale | Class A Common Stock | 301 | $4.16 footnote F2 | $1K | |
| ||||||
| Edward T. Mathers | Grant or award | Class A Common Stock | 3,911 | $0.00 | - | |
Item 5.02, 9.01
Item 2.02, 9.01
Item 5.02, 5.07, 9.01
Item 2.02, 9.01
OKUR insider trading FAQ
What is the latest insider trade for OKUR?
OnKure Therapeutics, Inc. (OKUR) had 14 insider filings in the last 90 days, with the most recent on 2026-09-23. The full record for OKUR runs to 48 Form 4 filings, the earliest from 2024-10-08. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying OKUR stock?
No insider purchases of OKUR were filed in the last 90 days.
How many insiders are selling OKUR stock?
2 insider sales of OKUR were filed in the last 90 days, totaling $1K.
Where can I see OKUR SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects OKUR Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Nicholas A. Saccomano view on EDGAR
- - Jason A. Leverone view on EDGAR
- - Isaac Manke view on EDGAR
- - Edward T. Mathers view on EDGAR
- - Liam Ratcliffe view on EDGAR
- - Andrew John Phillips view on EDGAR
- - Isaac Manke view on EDGAR
- - Valerie Malyvanh Jansen view on EDGAR
- - Michael G. Grey view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Insider activity in Health Care
- Where OKUR's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow OKUR with a 7-day demo
- OKUR on your watchlist
- Every OKUR Form 4 filing on record
- Up to 3 months of OKUR price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
